To present a brief review of periorbital cutaneous tumorogenesis, highlighting the steps which might be amenable to topical treatments and then discuss the use of topical agents in the management of periorbital skin malignancy.
A rapid expansion in the understanding of the pathogenesis of melanoma and nonmelanoma skin cancer has allowed the development of a number of topical agents targeting specific tumor-forming processes. Topical agents have been shown to be effective in the management of periorbital skin malignancy.
5-Fluorouracil and imiquimod have established roles in the management of periorbital skin malignancy. Newer agents such as ingenol mebutate, tazarotene, and diclofenac gel probably have evolving roles that require further research but show promise.
aEyelid, Lacrimal and Orbital Clinic, Royal Brisbane and Women's Hospital
bDepartment of Ophthalmology, University of Queensland, Brisbane, Queensland, Australia
Correspondence to Professor Timothy J. Sullivan, FRANZCO, FRACS, FRCOphth, Eyelid, Lacrimal and Orbital Clinic, Department of Ophthalmology, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Brisbane, QLD, 4029, Australia. E-mail: firstname.lastname@example.org